Fresh from a European initial public share offering that raised €41.8 million, ArGEN-X NV has advanced development of its lead antibody ARGX-110 for CD70-positive cancers, including plans for a US study in an incurable B-cell lymphoma. ---Subscribe to MedNous to access this article--- Company News
